HAE Financials

Income Statement
MetricQ1 2027Q4 2026Q3 2026Q2 2026Q1 2026
Revenue
339.4M
-2.0%
346.4M
+2.2%
339.0M
+3.6%
327.3M
+1.8%
321.4M
Cost of Revenue
136.6M
-7.8%
148.1M
+8.5%
136.6M
+3.0%
132.6M
+2.6%
129.2M
Gross Profit
202.8M
+2.3%
198.2M
-2.1%
202.4M
+3.9%
194.7M
+1.3%
192.2M
Operating Expenses
145.3M
-34.3%
221.2M
+63.9%
135.0M
-0.9%
136.3M
-1.5%
138.4M
R&D
16.2M
+12.1%
14.4M
+1.8%
14.2M
-4.6%
14.9M
-8.5%
16.3M
SG&A
118.9M
-1.6%
120.9M
+10.8%
109.2M
+7.4%
101.6M
-8.2%
110.7M
Operating Income
57.5M
+349.5%
-23025000
-134.2%
67.4M
+15.2%
58.5M
+8.6%
53.9M
EBITDA
84.6M
+11.7%
75.7M
-21.8%
96.8M
-0.6%
97.4M
+17.9%
82.6M
Net Income
33.0M
+263.8%
-20147000
-145.0%
44.7M
+15.7%
38.7M
+13.7%
34.0M
EPS (Basic)
$0.73
+265.9%
$-0.44
-145.8%
$0.96
+18.5%
$0.81
+14.1%
$0.71
EPS (Diluted)
$0.72
+267.4%
$-0.43
-145.3%
$0.95
+17.3%
$0.81
+15.7%
$0.70
Shares (Diluted)
45.7M
-1.5%
46.4M
-1.2%
47.0M
-1.4%
47.7M
-1.4%
48.4M
Haemonetics (HAE) โ€” Financials